Disclosed is a pharmaceutical composition for oral administration comprising the dihydropyridine calcium channel antagonist Lercanidipine or a pharmaceutical acceptable salt or polymorph thereof, as an active ingredient, and colloidal silicon dioxide from 5% to 25% by weight, to enhance bioavailability and/or improve solubility wherein the composition does not include both a disintegrant and a binder.